(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease.

An approach combining redundant controls to restrict the productive infection of adenoviruses to cells that are disrupted in the pRb pathway-a hallmark of human cancer-has resulted in a novel oncolytic virus that may be well suited for systemic administration to treat metastatic disease.